During our research, we identified 126 vascular disrupting agents that are being developed by close to 32 industry players and organizations for the treatment of different disease indications.
As can be observed in the figure, majority (40%) of the companies engaged in this domain are small firms (less than 50 employees). This is followed by large (17%), and very large (27%) companies. Examples of very large players include (in alphabetical order, no specific selection criteria) AbbVie, Celgene, Mayo Clinic, Novartis, Sanofi Genzyme, Takeda, Teva Pharmaceutical Industries and The University of Texas MD Anderson Cancer Center. Although the efforts for developing vascular disrupting agents have been undertaken by various players across the globe, majority (54%) of them are based in North America.
For additional details, please visit - https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
As can be observed in the following figure, majority of the vascular disrupting agents are currently in the phase II (52%) and phase I (36%) of clinical studies, while 7% are in phase III of clinical development or have been marketed. It is worth highlighting that vascular disrupting agent Padeliporfin (Steba biotech) has been marketed for prostate cancer. Other VDAs namely (arranged in alphabetical order) Bavituximab, Icaritin, NGR-TNF, Ofranergene obadenovec, Padeliporfin and Plinabulin, are currently in phase III of development for different indications and are likely to enter the market in the near future. Further, the phase II clinical development are mainly focused on the treatment of lung cancer and colorectal cancer.
As can be observed in the figure, majority (86%) of the development programs are focused on the treatment of solid tumors, primarily lung cancer and colorectal cancer. Examples of some popular vascular disrupting agents intended for the treatment of solid tumors include (in alphabetical order, no specific selection criteria) Bavituximab (Avid Bioservices), Cilengitide (Iceni Pharmaceuticals), Dolastatin 10, Fosbretabulin (Mateon Therapeutics), NGR-TNF (MolMed), and Ofranergene obadenovec (VBL Therapeutics).
As is evident from the following figure, MolMed is involved in the development of maximum (15) number of vascular disrupting agents for various disease indications; majority of these are in phase II of development. The drug developed by the company is a ligand-directed molecule.
The methodology adopted to identify the principal investigators of different clinical trials and to shortlist the most active individuals, is briefly described below:
1. As a starting point, we downloaded information on the ongoing / completed clinical trials related to vascular disrupting agents, registered between 2016 and January 2021 from www.clinicaltrials.gov.
2. We then captured details of the various principal investigators involved in the abovementioned trials. As a result, we came across 266 unique investigators, who were / are involved in different clinical studies related to vascular disrupting agents. It is important to mention that there were some studies for which information on principal investigators was not available, hence were not considered in this analysis.
3. From these unique investigators, we shortlisted 139 investigators who were involved in minimum of five clinical trials.
4. For each investigator, information on total number of publications, number of citations, number of clinical trials (ongoing and completed) conducted, ResearchGate score, number of connections on LinkedIn, and affiliations to various organizations / institutes, was collated.
5. The aforementioned input was then used to inform two important parameters for comparison, namely academic / research strength (based on the number of publications, number of citations, number of clinical trials, and work experience) and professional network (based on the number of connections on LinkedIn, and affiliations to various organizations / institutes) of each KOL considered in this analysis.
6. A 2×2 analysis based on the scores obtained for academic / research strength (abscissa) and professional network (ordinate) was performed for these KOLs.
7. Further, for each KOL, a Roots Analysis (RA) proprietary score was calculated based on the scores for the abovementioned parameters, depending on the key achievements, strengths and the activeness of the individual in the clinical studies. The RA score was then compared and validated with scores given by a third party.
8. Top investigators, based on our scoring criteria, were further shortlisted and represented on 2-dimensional plane, highlighting the most prominent investigators (in terms of professional network and academic / research strength).
Key Questions Answered
- Who are the leading industry and non-industry players in this market?
- Which cancer indications can be treated with vascular disrupting agents?
- Which geographies are the most active in conducting clinical trials on vascular disrupting agents?
- What is the focus area of the research activities ongoing in this domain?
- Which are the leading administering institute centers supporting the research related to this domain?
- Who are the key opinion leaders that can help you drive your development efforts?
- How is the current and future market opportunity likely to be distributed across key market
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
